Skip to main content
Strategic Partners A/S logo

Strategic Partners A/S — Investor Relations & Filings

Ticker · STRAP ISIN · DK0062502894 LEI · 54930025OZD2GGSQ7L42 CO Financial and insurance activities
Open in API
Filings indexed 501 across all filing types
Latest filing 2018-03-15 Annual Report
Country DK Denmark
Listing CO STRAP

About Strategic Partners A/S

https://www.strategic-partners.dk/

Strategic Partners A/S is an investment company that engages in strategic partnerships with businesses that have significant potential. The company's strategy involves taking an active ownership role to create value through its competencies. In addition to its primary focus, the firm may also invest in other equity interests and properties to generate returns. Formerly known as Orphazyme A/S, the company sold its biotechnology activities in May 2022. A new board and management team was appointed in May 2023, and the company officially adopted its new strategy, purpose, and name in October 2024.

Recent filings

Filing Released Lang Actions
Orphazyme announces Annual Report 2017
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2017' and contains comprehensive sections including a letter from the CEO, key financial figures, business review, corporate governance, and full financial statements with auditor's report. It covers the company's activities and financial performance for the fiscal year 2017, fitting the definition of an Annual Report (10-K). FY 2017
2018-03-15 English
Orphazyme announces Annual Report 2017
Report Publication Announcement Classification · 100% confidence The document is a short announcement (4,716 characters) from Orphazyme A/S titled 'Orphazyme announces Annual Report 2017'. It explicitly states that the full report is attached as a PDF and provides a summary of highlights, business progress, and financial guidance. Following the 'Menu vs Meal' rule, this is an announcement of a report rather than the full 10-K/Annual Report itself, making it a Report Publication Announcement (RPA).
2018-03-15 English
Capital increase of 11,380 shares (equivalent to approximately 0.06% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement from Orphazyme A/S detailing a specific capital increase of 11,380 shares resulting from an issue of bonus shares to KLSDC and UCLB. It describes the mechanics of the share issuance, the impact on total share capital, and the expected listing date. This falls under the category of share issuance or capital changes.
2018-01-29 English
Capital increase of 11,380 shares (equivalent to approximately 0.06% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement regarding a capital increase through the issuance of bonus shares. It details the number of shares issued, the reason for the issuance (license agreement), and the impact on the total share capital. This falls under the category of share issuance or capital changes.
2018-01-29 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a formal company announcement from Orphazyme A/S dated January 19, 2018. The core subject is the announcement that their drug candidate, arimoclomol, received 'rare pediatric disease designation' from the US FDA for treating Niemann-Pick disease Type C (NPC). This type of announcement, detailing regulatory milestones, drug development updates, and associated incentives (like Priority Review Vouchers), is characteristic of communications aimed at investors regarding pipeline progress. It is not a full financial report (10-K or IR), a transcript (CT), or a general dividend notice (DIV). It specifically relates to regulatory progress and investor information, making 'Investor Presentation' (IP) or 'Regulatory Filings' (RNS) potential candidates. However, given the detailed nature of the regulatory achievement and its implications for the drug pipeline, it functions as a specific regulatory update that is highly relevant to investors. Since there is no specific code for 'Regulatory Milestone Announcement' and it is not a general regulatory filing (RNS) but a specific, positive development announcement, it aligns best with the general category of investor-focused updates. Since it is not a presentation (IP) but a press release detailing a regulatory event, and it doesn't fit other specific categories like M&A (TAR) or Director's Dealing (DIRS), the most appropriate classification among the provided options for a specific, non-financial, non-meeting regulatory/pipeline update is often RNS, or if it's considered a key piece of investor information, IP. Given the content is a press release announcing a specific FDA designation, it is a regulatory announcement. If it were a general filing, RNS would apply. Since it details a specific regulatory achievement that impacts the company's value proposition, it is a significant regulatory/investor update. In the absence of a dedicated 'Regulatory Update' code, and noting it is not a formal financial report, RNS (Regulatory Filings - general fallback) is a strong candidate, but 'Investor Presentation' (IP) often covers press releases detailing strategic/regulatory progress intended for investors. Given the context of biotech pipeline updates, this is a key piece of investor information. However, since it is a press release announcing a regulatory event, RNS is the most accurate fallback for non-standard regulatory news. Let's re-evaluate: It is a press release announcing an FDA designation. This is a specific regulatory event. It is not a general filing (RNS), nor is it a presentation (IP). It is a specific announcement. If we look at the definitions, it doesn't fit perfectly. It is a regulatory update. RNS is the fallback for miscellaneous filings. I will classify it as RNS as it is a specific regulatory announcement that doesn't fit the other specific categories like ER, IR, or CAP.
2018-01-19 English
Arimoclomol for NPC receives Rare Pediatric Disease Designation
Regulatory Filings Classification · 95% confidence The document is a corporate announcement from Orphazyme A/S regarding a regulatory milestone (FDA Rare Pediatric Disease Designation). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement (RPA) as it is the primary announcement itself. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2018-01-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.